{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:22:14Z","timestamp":1787800934341,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Current recommendations do not support the use of anti-reflux medications to treat gastro-oesophageal reflux disease (GORD) among preterm infants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To describe the prevalence of GORD and the use of anti-reflux medications amongst very preterm infants (&lt;32 weeks\u2019 gestational age (GA)) in neonatal units in England and Wales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>Retrospective cohort study using the National Neonatal Research Database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 58,108 infants [median GA (IQR) 29 (27\u201330) weeks], 15.8% (<jats:italic>n<\/jats:italic>\u2009=\u20099191) had a diagnosis of GORD and 36.9% (<jats:italic>n<\/jats:italic>\u2009=\u200912,446) received anti-reflux medications. Those who received anti-reflux medications were more preterm [GA, median (IQR): medications, 28 (26\u201330) vs. no medications, 30 (28\u201331); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001] and had lower birth weight [mean (SD): medications, 1124\u2009g (354) vs. no medications, 1265\u2009g (384); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001]. Most (57%, <jats:italic>n<\/jats:italic>\u2009=\u200912,224) received Gaviscon, or Histamine-2 Receptor Antagonist (H2RA) (56%, <jats:italic>n<\/jats:italic>\u2009=\u200911,959). Over time, prokinetic use has declined substantially, the use of H2RAs and Gaviscon has reduced although they continue to be used frequently, whilst the use of PPIs has increased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-reflux medications are frequently prescribed in very preterm infants, despite evidence to suggest that they are not effective and may be harmful. Clear guidelines for diagnosing GORD and the use of anti-reflux medications are required to rationalise the pharmacological management of GORD in preterm infants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Impact<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p>Anti-reflux medications are frequently prescribed, often without a diagnosis of gastro-oesophageal reflux disease, to very preterm infants while in the neonatal unit and at discharge.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Half of the infants born at &lt;28 weeks\u2019 gestational age receive anti-reflux medications in hospital and a quarter are discharged home on them.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Although the use of prokinetics declined following alerts of adverse events, histamine2-receptor antagonists and alginates such as Gaviscon continue to be used and the use of proton-pump inhibitors has increased more than 2-fold.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41390-021-01821-y","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T18:02:58Z","timestamp":1635530578000},"page":"520-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-reflux medication use in preterm infants"],"prefix":"10.1038","volume":"92","author":[{"given":"Haslina","family":"Binti Abdul Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Szatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Budge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MPG.0000000000001889","volume":"66","author":"R Rosen","year":"2018","unstructured":"Rosen, R. et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 66, 516\u2013554 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1821_CR2","unstructured":"The National Institute for Health and Care Excellence (NICE). Gastro-oesophageal Reflux Disease in Children and Young People: Diagnosis and Management (2019)."},{"key":"1821_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1542\/hpeds.2013-0036","volume":"3","author":"SR Jadcherla","year":"2013","unstructured":"Jadcherla, S. R. et al. Practice variance, prevalence, and economic burden of premature infants diagnosed with GERD. Hosp. Pediatr. 3, 335\u2013341 (2013).","journal-title":"Hosp. Pediatr."},{"key":"1821_CR4","unstructured":"BMJ Group, Pharmaceutical Press, and RCPCH Publications, London. Paediatric Formulary Committee. BNF for Children (online) http:\/\/www.medicinescomplete.com (2019)."},{"key":"1821_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ANC.0b013e3181a88358","volume":"9","author":"CK Barney","year":"2009","unstructured":"Barney, C. K. et al. Lansoprazole, ranitidine, and metoclopramide: comparison of practice patterns at 4 level III NICUs within one healthcare system. Adv. Neonatal Care Off. J. Natl Assoc. Neonatal Nurses 9, 129\u2013131 (2009).","journal-title":"Adv. Neonatal Care Off. J. Natl Assoc. Neonatal Nurses"},{"key":"1821_CR6","doi-asserted-by":"publisher","first-page":"e0214135","DOI":"10.1371\/journal.pone.0214135","volume":"14","author":"VS Santos","year":"2019","unstructured":"Santos, V. S. et al. Association between histamine-2 receptor antagonists and adverse outcomes in neonates: a systematic review and meta-analysis. PLoS ONE 14, e0214135 (2019).","journal-title":"PLoS ONE"},{"key":"1821_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1542\/peds.2018-1061","volume":"142","author":"EC Eichenwald","year":"2018","unstructured":"Eichenwald, E. C. Diagnosis and management of gastroesophageal reflux in preterm infants. Pediatrics 142, 11 (2018).","journal-title":"Pediatrics"},{"key":"1821_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jpeds.2016.03.059","volume":"174","author":"JL Slaughter","year":"2016","unstructured":"Slaughter, J. L., Stenger, M. R., Reagan, P. B. & Jadcherla, S. R. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States Children\u2019s Hospitals. J. Pediatr. 174, 63\u201370.e3 (2016).","journal-title":"J. Pediatr."},{"key":"1821_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1542\/peds.2007-0381","volume":"121","author":"WF Malcolm","year":"2008","unstructured":"Malcolm, W. F. et al. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 121, 22\u201327 (2008).","journal-title":"Pediatrics"},{"key":"1821_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1651-2227.2004.tb00680.x","volume":"93","author":"A Dhillon","year":"2007","unstructured":"Dhillon, A. & Ewer, A. Diagnosis and management of gastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr. 93, 88\u201393 (2007).","journal-title":"Acta Paediatr."},{"key":"1821_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/apa.14073","volume":"107","author":"T Rossor","year":"2018","unstructured":"Rossor, T., Andradi, G., Bhat, R. & Greenough, A. Investigation and management of gastro-oesophageal reflux in United Kingdom neonatal intensive care units. Acta Paediatr. 107, 48\u201351 (2018).","journal-title":"Acta Paediatr."},{"key":"1821_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/archdischild-2015-309928","volume":"101","author":"C Gale","year":"2016","unstructured":"Gale, C. & Morris, I. The UK National Neonatal Research Database: using neonatal data for research, quality improvement and more. Arch. Dis. Child.\u2014Educ. Pract. Ed. 101, 216\u2013218 (2016).","journal-title":"Arch. Dis. Child.\u2014Educ. Pract. Ed."},{"key":"1821_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.pcl.2018.12.012","volume":"66","author":"IK Gulati","year":"2019","unstructured":"Gulati, I. K. & Jadcherla, S. R. Gastroesophageal reflux disease in the neonatal intensive care unit infant: who needs to be treated and what approach is beneficial? Pediatr. Clin. North Am. 66, 461\u2013473 (2019).","journal-title":"Pediatr. Clin. North Am."},{"key":"1821_CR14","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1097\/pq9.0000000000000394","volume":"6","author":"FM Shakeel","year":"2021","unstructured":"Shakeel, F. M. et al. Decreasing inappropriate use of antireflux medications by standardizing gastroesophageal reflux disease management in NICU. Pediatr. Qual. Saf. 6, e394 (2021).","journal-title":"Pediatr. Qual. Saf."},{"key":"1821_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/MPG.0000000000000968","volume":"62","author":"A Funderburk","year":"2016","unstructured":"Funderburk, A. et al. Temporal association between reflux-like behaviors and gastroesophageal reflux in preterm and term infants. J. Pediatr. Gastroenterol. Nutr. 62, 556\u2013561 (2016).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1821_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/MPG.0b013e3181b7f563","volume":"49","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas, Y. et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J. Pediatr. Gastroenterol. Nutr. 49, 498\u2013547 (2009).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1821_CR17","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1542\/peds.2011-0796","volume":"129","author":"G Terrin","year":"2012","unstructured":"Terrin, G. et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 129, e40\u2013e45 (2012).","journal-title":"Pediatrics"},{"key":"1821_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pedneo.2013.01.011","volume":"54","author":"A Bilali","year":"2013","unstructured":"Bilali, A., Galanis, P., Bartsocas, C., Sparos, L. & Velonakis, E. H2-blocker therapy and incidence of necrotizing enterocolitis in preterm infants: a case-control study. Pediatr. Neonatol. 54, 141\u2013142 (2013).","journal-title":"Pediatr. Neonatol."},{"key":"1821_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2036.2010.04545.x","volume":"33","author":"L Corvaglia","year":"2011","unstructured":"Corvaglia, L. et al. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharm. Ther. 33, 466\u2013470 (2011).","journal-title":"Aliment Pharm. Ther."},{"key":"1821_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1177\/0091270009338483","volume":"50","author":"B Atasay","year":"2010","unstructured":"Atasay, B., Erdeve, O., Arsan, S. & T\u00fcrmen, T. Effect of sodium alginate on acid gastroesophageal reflux disease in preterm infants: a pilot study. J. Clin. Pharmacol. 50, 1267\u20131272 (2010).","journal-title":"J. Clin. Pharmacol."},{"key":"1821_CR21","first-page":"CD003211","volume":"12","author":"TC Kwok","year":"2017","unstructured":"Kwok, T. C., Ojha, S. & Dorling, J. Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database Syst. Rev. 12, CD003211 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1821_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.mpg.0000252190.97545.07","volume":"44","author":"TI Omari","year":"2007","unstructured":"Omari, T. I., Haslam, R. R., Lundborg, P. & Davidson, G. P. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J. Pediatr. Gastroenterol. Nutr. 44, 41\u201344 (2007).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1821_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1067\/S0022-3476(03)00207-5","volume":"143","author":"DJ Moore","year":"2003","unstructured":"Moore, D. J. et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J. Pediatr. 143, 219\u2013223 (2003).","journal-title":"J. Pediatr."},{"key":"1821_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jpeds.2013.05.007","volume":"163","author":"G Davidson","year":"2013","unstructured":"Davidson, G. et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J. Pediatr. 163, 692\u2013698.e2 (2013).","journal-title":"J. Pediatr."},{"key":"1821_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jpeds.2008.09.054","volume":"154","author":"SR Orenstein","year":"2009","unstructured":"Orenstein, S. R., Hassall, E., Furmaga-Jablonska, W., Atkinson, S. & Raanan, M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J. Pediatr. 154, 514\u2013520.e4 (2009).","journal-title":"J. Pediatr."},{"key":"1821_CR26","doi-asserted-by":"publisher","unstructured":"Sand, L. et al. Observational cohort study of changing trends in non-invasive ventilation in very preterm infants and associations with clinical outcomes. Arch. Dis. Child. Fetal Neonatal Ed. https:\/\/doi.org\/10.1136\/archdischild-2021-322390 (2021).","DOI":"10.1136\/archdischild-2021-322390"},{"key":"1821_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41390-020-0932-4","volume":"89","author":"SR Jadcherla","year":"2021","unstructured":"Jadcherla, S. R. et al. Role of feeding strategy bundle with acid-suppressive therapy in infants with esophageal acid reflux exposure: a randomized controlled trial. Pediatr. Res. 89, 645\u2013652 (2021).","journal-title":"Pediatr. Res."},{"key":"1821_CR28","doi-asserted-by":"publisher","first-page":"e000287","DOI":"10.1136\/bmjpo-2018-000287","volume":"2","author":"E Dermyshi","year":"2018","unstructured":"Dermyshi, E., Mackie, C., Kigozi, P., Schoonakker, B. & Dorling, J. Antacid therapy for gastroesophageal reflux in preterm infants: a systematic review. BMJ Paediatr. Open 2, e000287 (2018).","journal-title":"BMJ Paediatr. Open"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01821-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T20:15:50Z","timestamp":1664482550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1038\/s41390-021-01821-y","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the Yorkshire & The Humber\u2014Leeds East Research Ethics Committee and Health and Care Research Wales (HCRW) (REC reference: 18\/YH\/0209; Date of approval: 25 May 2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not asked from individuals whose data were included in this study as the historical data used were held in the pre-existing, REC-approved NNRD. Data held in the NNRD are de-identified and no patient identifiers were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Publication consent was not asked from individuals whose data were included in this study as the historical data used were held in the pre-existing, REC-approved NNRD. Data held in the NNRD are de-identified and no patient identifiers were used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}